Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
B cells are essentially described for their capacity to produce antibodies ensuring anti‐infectious immunity or deleterious responses in the case of autoimmunity or allergy. However, abundant data described their ability to restrain inflammation by diverse mechanisms. In allergy, some regulatory B‐cell subsets producing IL‐10 have been recently described as potent suppressive cells able to restrain inflammatory responses both in vitro and in vivo by regulatory T‐cell differentiation or directly inhibiting T‐cell‐mediated inflammation. A specific deficit in regulatory B cells participates to more severe allergic inflammation. Induction of allergen tolerance through specific immunotherapy induces a specific expansion of these cells supporting their role in establishment of allergen tolerance. However, the regulatory functions carried out by B cells are not exclusively IL‐10 dependent. Indeed, other regulatory mechanisms mediated by B cells are (i) the production of TGF‐β, (ii) the promotion of T‐cell apoptosis by Fas–Fas ligand or granzyme‐B pathways, and (iii) their capacity to produce inhibitory IgG4 and sialylated IgG able to mediate anti‐inflammatory mechanisms. This points to Bregs as interesting targets for the development of new therapies to induce allergen tolerance. In this review, we highlight advances in the study of regulatory mechanisms mediated by B cells and outline what is known about their phenotype as well as their suppressive role in allergy from studies in both mice and humans.